Advertisement

Störungen der Neurotransmission assoziiert mit neurologischen und psychiatrischen Syndromen

  • G. Brune
  • H.-W. Richter
Conference paper

Zusammenfassung

Aufgrund einer mehr als 20jährigen systematischen Forschung wird heute allgemein angenommen, daß neben dem Acetylcholin biogene Amine, wie Dopamin, Noradrenalin und Serotonin, und darüber hinaus chemische Verbindungen, wie z. B. Glycin, Glutaminsäure und γ-Aminobuttersäure, als Neurotransmitter für die Funktionen des Nervensystems von Bedeutung sind [3, 11, 12, 14, 20, 21, 39, 45, 52, 63, 127, 154]. Diese Annahme schließt ein, daß unterschiedliche Pathomechanismen im Bereich der Neurotransmission, wie z. B. Veränderungen im Stoffwechsel der Neurotransmitter bzw. strukturelle oder funktionelle Läsionen der prä- und/oder postsynaptischen Elemente, Störungen der Funktionen des Nervensystems bedingen und das Entstehen neurologischer und/oder psychiatrischer Syndrome bewirken. Die Erforschung von Physiologie und Pathophysiologie der Neurotransmission hat somit für die Nervenheilkunde zunehmend an Bedeutung gewonnen. Ini Rahmen dieses Referates sollen Erkenntnisse und Probleme bezüglich der Pathophysiologie der Neurotransmission im Zusammenhang mit einigen klinischen Syndromen besprochen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abdou, N.I., Lisak, R.P., Zweiman, B., Abrahamsohn, I., Penn, A.S.: The thymus in myasthenia gravis: Evidence for altered population. New Engl. J. Med. 291 1221–1275 (1974)CrossRefGoogle Scholar
  2. 2.
    Akaiskal, H.S., McKinney, W.T. jr.: Overview of recent research in depression. Arch. gen. Psychiat. 32 285–305 (1975)CrossRefGoogle Scholar
  3. 3.
    Amin, A.H., Crawford, T.B.B., Gaddum, J.H.: The distribution of substance P and 5-hydroxytryptamine in the central nervous system in the dog. J.Physiol. 126, 596 (1954)PubMedGoogle Scholar
  4. 4.
    Andén, N.E., Carlsson, A., Dahlström, A., Fuxe, K., Hillarp, N.A., Larssen, K.: Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 3, 523 (1964)PubMedCrossRefGoogle Scholar
  5. 5.
    Andén, N.E., Dahlström, A., Fuxe, K., Larsson, K.: Further evidence for the presence of nigro-neostriatal dopamine neurons in the rat. Amer.J.Anat. 116, 329 (1965)PubMedCrossRefGoogle Scholar
  6. 6.
    Barbeau, A.: The pathogenesis of Parkinson’s disease: A new hypothesis. Canad.med.Ass.J. 87, 802 (1962)PubMedGoogle Scholar
  7. 7.
    Barbeau, A., Campanella, G., Butterworth, R.F., Yamada, K.: Uptake and efflux of C-dopamine in platelets: Evidence for a generalized defect in Parkinson’s disease. Neurology 25, 1–9 (1975)PubMedCrossRefGoogle Scholar
  8. 8.
    Bartholini, G., Pletscher, A.: Cerebral accumulation and metabolism of 14C-dopa after selective inhibition of peripheral decarboxylase. J.Pharmacol.exp.Ther. 161, 14 (1968)PubMedGoogle Scholar
  9. 9.
    Bartholini, G., Pletscher, A.: Enhancement of tyrosine hydroxylation within the brain by chlorpromazine. Experientia (Basel) 25, 919 (1969)CrossRefGoogle Scholar
  10. 10.
    Bergsman, A.: Urinary excretion of adrenalin and noradrenalin in some mental diseases: Clinical and experimental study. Acta psychiat. scand. 34, 5 (1939)Google Scholar
  11. 11.
    Bernheimer, H., Birkmayer, W., Hornykiewicz, O.: Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin.Wschr. 39, 1056 (1961)PubMedCrossRefGoogle Scholar
  12. 12.
    Bertler, A.: Occurence and localization of catecholamines in the human brain. Acta physiol. scand. 51, 97 (1961)CrossRefGoogle Scholar
  13. 13.
    Bertler, A., Falck, B., Owman, C., Rosengren, E.: The localization of monoaminergic blood-brain barrier mechanisms. Pharmacol. Rev. 18, 369 (1966)PubMedGoogle Scholar
  14. 14.
    Bertler, A., Rosengren, E.: Occurence and distribution of dopamine in brain and other tissues. Experientia (Basel) 15, 10 (1959)CrossRefGoogle Scholar
  15. 15.
    Bertler, A., Rosengren, E.: Occurence and distribution of catecholamines in brain. Acta physiol. scand. 47, 350 (1959)PubMedGoogle Scholar
  16. 16.
    Birkmayer, W., Hornykiewicz, O.: Der L-3,4-Dioxyphenylalanin (= Dopa)-Effekt bei der Parkinson-Akinese. Wien.klin.Wschr. 73, 787 (1961)PubMedGoogle Scholar
  17. 17.
    Birkmayer, W., Hornykiewicz, O.: Der L-Dioxyphenylalanin (= L-Dopa)-Effekt beim Parkinson-Syndrom des Menschen. Zur Pathogenese und Behandlung der Parkinson-Akinese. Arch. Psychiat. Nervenkr. 203, 560 (1962)PubMedCrossRefGoogle Scholar
  18. 18.
    Birkmayer, W., Hornykiewicz, O.: Weitere experimentelle Untersuchungen über L-Dopa beim Parkinson-Syndrom und Reserpin-Parkinsonismus. Arch.Psychiat. Nervenkr. 206, 367 (1964)CrossRefGoogle Scholar
  19. 19.
    Bleuler, M., Stoll, W.: Clinical use of reserpine in psychiatry: Comparison with chlorpromazine. Ann.N.Y.Acad.Sci. 61, 167 (1955)PubMedCrossRefGoogle Scholar
  20. 20.
    Bogdanski, D.F., Udenfriend, S.: Serotonin and monoamine oxidase in brain. J.Pharmacol. 116, 7 (1956)Google Scholar
  21. 21.
    Bogdanski, D.F., Weissbach, H., Udenfriend, S.: The distribution of serotonin, 5-hydroxytryptophane decarboxylase and monoamine oxidase in brain. J.Neurochem. 1, 272 (1957)PubMedCrossRefGoogle Scholar
  22. 22.
    Brodie, B.B., Corner, M.S., Costa, E., D’Labac, A.: The role of brain serotonin in the mechanism of the central action of reserpine. J.Pharmacol.exp.Ther. 152, 340 (1966)PubMedGoogle Scholar
  23. 23.
    Brodie, B.B., Shore, P.A.: A concept for a role of serotonine and norepinephrine as chemical mediators in the brain. Ann.N.Y.Acad.Sci. 66, 631 (1957)PubMedCrossRefGoogle Scholar
  24. 24.
    Brown, G.L., Dale, H.H., Feldberg, W.: Reactions of the normal mammalian muscle to acetylcholine and to eserine. J.Physiol. (Lond.) 87, 394 (1936)Google Scholar
  25. 25.
    Brune, G.G.: The somatically determined psychoses. In: Biochemistry, Schizophrenias and Affective Illnesses (Ed. by Harold E. Himwich ), S. 43–78. Baltimore: Williams and Wilkins 1970Google Scholar
  26. 26.
    Brune, G.G., Pflughaupt, K.-W.: Effects of L-Dopa treatment on indole metabolism in Parkinson’s disease. Experientia (Basel) 27, 516 (1971)CrossRefGoogle Scholar
  27. 27.
    Bueno, J.R., Himwich, H.E.: A dualistic approach to some biochemical problems in endogenous depressions. Psychosomatics 8, 82–94 (1967)PubMedGoogle Scholar
  28. 28.
    Bunney, W.E. jr., Davis, J.M.: Norepinephrine in depressive reactions. A review. Arch.gen. Psychiat. 13, 483 (1965)CrossRefGoogle Scholar
  29. 29.
    Bunney, W.E. jr., Murphy, D.L., Brody, K.H., Goddwin, S.K.: L-Dopa in depressed patients. Lancet 19701, 352Google Scholar
  30. 30.
    Burkard, W.P., Gey, K.F., Pletscher, A.: Activation of tyrosine hydroxylation in rat brain by chlorpromazine. Nature (Lond.) 213, 732 (1967)CrossRefGoogle Scholar
  31. 31.
    Cares, R.M., Buckmann, C.: Comparative review of the structure and side effects of newer psychotropic agents. Dis.nerv.Syst. 24, Suppl. 4, 92 (1963)Google Scholar
  32. 32.
    Carlsson, A., Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta pharmacol. (Kbh.) 20, 140 (1963)CrossRefGoogle Scholar
  33. 33.
    Carlsson, A., Lindqvist, M., Magnusson, T.: 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature (Lond.) 180, 1200 (1957)CrossRefGoogle Scholar
  34. 34.
    Carlsson, A., Rosengren, E., Bertler, A., Nilsson, J.: Effect of reserpine on the metabolism of catecholamines. In: Psychotic drugs ( S. Garattini and V. Ghetti, Eds.). Amsterdam: Elsevier 1957Google Scholar
  35. 35.
    Caroll, J., Mowbray, R.M., Davies, B.: Sequential comparison of L-tryptophan with E.C.T. in severe depression. Lancet 1970 I, 967CrossRefGoogle Scholar
  36. 36.
    Del Castillo, J., Katz, B.: The membrane change produced by the neuromuscular transmitter. J.Physiol. (Lond.) 125, 546 (1954)Google Scholar
  37. 37.
    Chang, C.C., Chen, T.F., Chuang, S.T.: Influence of chronic neostigmine on the number of acethylcholine receptors and the release of acethylcholine from the rat diaphragm. J.Physiol. (Lond.) 230, 613 (1973)Google Scholar
  38. 38.
    Cherington, M.: Botulism. Ten-Year Experience. Arch.Neurol. (Chic.) 30, 432 (1974)CrossRefGoogle Scholar
  39. 39.
    Cooper, J.R., Bloom, F.E., Roth, R.H.: y-Aminobutyric Acid, Glycine, and Glutamic Acid. In: The Biochemical Basis of Neuropharmacology. S. 202. New York—London—Toronto: Oxford University Press 1974Google Scholar
  40. 40.
    Coppen, A.: The biochemistry of affective disorders. Brit.J.Psychiat. 113, 1237 (1967)PubMedCrossRefGoogle Scholar
  41. 41.
    Coppen, A., Prange, A.J. jr., Whybrow, P.C., Noguera, R.: Abnormalities of indolamines in affective disorders. Arch.gen.Psychiat. 26, 474 (1972)PubMedCrossRefGoogle Scholar
  42. 42.
    Coppen, A., Shaw, D.M., Herzberg, B., Maggs, R.: Tryptophan in the treatment of depression. Lancet 1967 1, 1178CrossRefGoogle Scholar
  43. 43.
    Coppen, A., Shaw, D.M., Malleson, A., Eccleston, E., Gundy, G.: Tryptamine metabolism in depression. Brit.J.Psychiat. 111, 993 (1965)PubMedCrossRefGoogle Scholar
  44. 44.
    Corrodi, H., Fuxe, K., Hokfelt, T., Schou, M.: The effect of lithium on cerebral monoamine neurons. Psychopharmacologia (Berl.) 11, 345 (1967)CrossRefGoogle Scholar
  45. 45.
    Costa, E., Aprison, M.H.: Studies on the 5-hydroxytryptamine (serotonin) content in human brain. J.nerv.ment.Dis. 126, 289 (1958)PubMedCrossRefGoogle Scholar
  46. 46.
    Cotzias, G.C., Papavasiliou, P.S., Düby, S.E., Steck, A.J., Ginos, J.Z.: Some newer metabolic concepts in the treatment of parkinsonism. Neurology (Minneap.) 22, 82 (1972)CrossRefGoogle Scholar
  47. 47.
    Cotzias, G.C., van Woert, M.H., Schiffer, L.M.: Aromatic amino acids and modification of Parkinsonism. New Engl.J.Med. 276, 374 (1967)PubMedCrossRefGoogle Scholar
  48. 48.
    Curtis, B.C., Cleghom, R.A., Sourkes, T.L.: The relationship between affect on the excretion of adrenaline, noradrenaline, and 17-hydroxycorticosteroids. J.psychosom.Res. 4, 176 (1960)PubMedCrossRefGoogle Scholar
  49. 49.
    Dale, H.H.: Transmission of nervous effects by acetylcholine. Harvey Lect. 32, 229 (1936)Google Scholar
  50. 50.
    Degkwitz, R., Frowein, R., Kulenkampff, C., Mohs, U.: Ober die Wirkung des L-dopa beim Menschen und deren Beeinflussung durch Reserpin, Chlorpromazin, Iproniazid und Vitamin B6. Klin.Wschr. 38, 120 (1960)PubMedCrossRefGoogle Scholar
  51. 51.
    Desmedt, J.E.: Presynaptic mechanism in myasthenia gravis. Ann.N.Y.Acad.Sci. 135, 209 (1966)PubMedCrossRefGoogle Scholar
  52. 52.
    Ehringer, H., Hornykiewicz, O.: Verteilung von Noradrenalin und Dopamin (3-Hydroxytryptamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin.Wschr. 38, 1236 (1960)PubMedCrossRefGoogle Scholar
  53. 53.
    Elmquist, D., Hofmann, W.W., Kugelberg, J., Quastel, D.M.J.: An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J.Physiol. (Lond.) 174, 417 (1964)Google Scholar
  54. 54.
    Elmqvist, D., Lambert, E.H.: Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin.Proc. 43, 689 (1968)PubMedGoogle Scholar
  55. 55.
    Engel, A.G., Lambert, E.H., Santa, T.: Study of long-term anticholinesterase therapy. Neurology (Minneap.) 23, 1273 (1973)CrossRefGoogle Scholar
  56. 56.
    Engel, A.G., Santa, T.: Histometric analyses of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann.N.Y.Acad.Sci. 183, 46 (1971)PubMedCrossRefGoogle Scholar
  57. 57.
    Engel, A.G., Santa, T.: Motor Endplate Fine Structure. Quantitative Analysis in Disorders of Neuromuscular Transmission and Prostigmine-induced Alterations. In: New Developments in EMG and Clinical Neurophysiology (J.E. Desmedt, Ed.), Vol. 1, Basel: Karger 1973Google Scholar
  58. 58.
    Engel, A.G., Tsujihata, M.: The Motor End Plate in Myasthenia Gravis and in Experiental Autoimmune Myasthenia gravis. A Quantitative Ultrastructural Study. In: Myasthenia Gravis. Annals of the New York Academy of Sciences (Ed. David Grob). Ann.N.Y.Acad.Sci. 274, 60 (1976)CrossRefGoogle Scholar
  59. 59.
    Everett, G.M., Borcherding, J.W.: L-Dopa: Effect on concentrations of dopamine, norepine-phrine, and serotonin in brain of mice. Science 168, 849 (1970)PubMedCrossRefGoogle Scholar
  60. 60.
    Fambrough, D.M., Drachman, D.B.: Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors. Science 182, 293 (1972)CrossRefGoogle Scholar
  61. 61.
    Fatt, P., Katz, B.: Spontaneous subthreshold activity at motor nerve endings. J.Physiol. (Lond.) 117, 109 (1952)Google Scholar
  62. 62.
    Fehling, C.: Treatment of Parkinson’s disease with L-Dopa: double blind study. Acta psychiat. scand. 42, 367 (1966)Google Scholar
  63. 63.
    Feldberg, W., Vogt, M.: Acetylcholine synthesis in different regions of the central nervous system. J.Physiol. (Lond.) 107, 372 (1948)Google Scholar
  64. 64.
    Feldhues, A., Brune, G.G.: Panoramawechsel des Parkinsonismus. Fortschr.Med. 90, 1141Google Scholar
  65. 65.
    Frohman, C.E., Warner, K.A., Barry, C.T., Arthur, R.E.: Amino acid transport and the plasma factor in schizophrenia. Biol. Psychiat. 1, 201 (1969)PubMedGoogle Scholar
  66. 66.
    Glowinski, J., Axelrod, J.: Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds. Nature (Lond.) 204, 1318 (1964)CrossRefGoogle Scholar
  67. 67.
    Goldman, AJ., Hermann, Chr. jr., Keesey, J.C., Mulder, D.G., Brown, W.J.: Myasthenia gravis and invasive thymoma: A 20-year experience. Neurology (Minneap.) 25, 1021 (1975)CrossRefGoogle Scholar
  68. 68.
    Goodwin, S.K., Murphy, D.L., Brody, H.K.H., Bunney, W.E.: L-dopa catecholamines and behavior: A clinical and biochemical study in depressed patients. Biol.Psychiat. 2, 342 (1970)Google Scholar
  69. 69.
    Goodwin, S.K., Post, R.M., Dunner, D.L., Gordon, E.K.: Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique. AmerJ.Psychiat. 130, 73 (1973)Google Scholar
  70. 70.
    Gordon, E.K., Oliver, J.: 3-methoxy-4-hydroxyphenylethylene glycol in human cerebrospinal fluid. Clin.Chim.Acta 35, 145 (1971)PubMedCrossRefGoogle Scholar
  71. 71.
    Greenspan, K. et al.: Catecholamine metabolism in affective disorders. 3 MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J.Psychiat.Res. 7, 171 (1970)PubMedCrossRefGoogle Scholar
  72. 72.
    Grob, D., Namba, T.: Characteristics and mechanism of neuromuscular block in myasthenia gravia. Ann.N.Y.Acad.Sci. 274, 143 (1976)PubMedCrossRefGoogle Scholar
  73. 73.
    Hanzal, F.: Behandlung des Parkinson-Syndroms mit L-Dopa und L-Carbidopa. Münch.med. Wschr. 118, 653 (1976)Google Scholar
  74. 74.
    Harris, T.H.: Depression induced by Rauwolfia compounds. Amer J.Psychiat. 113, 950 (1957)PubMedGoogle Scholar
  75. 75.
    Harris, AJ., Miledi, R.: The effect of type D botulinum toxin on frog neuromuscular junctions. J.Physiol. (Lond.) 217, 497 (1971)Google Scholar
  76. 76.
    Haskovec, L., Rysanek, K.: Die Wirkung von Lithium auf den Metabolismus der Katecholamine und Indolalkylamine beim Menschen. Arzneimittel-Forsch. 19, 426 (1969)Google Scholar
  77. 77.
    Hassler, R.: Zur Pathologie der Paralysis agitans and des postencephalitischen Parkinsonismus. J.Psychol.Neurol. (Lpz.) 48, 387 (1938)Google Scholar
  78. 78.
    Hertting, G., Axelrod, J., Whitby, L.G.: Effect of drugs on the uptake and metabolism of H3 -norepinephrine. J.Pharmacol.exp.Ther. 134, 146 (1961)Google Scholar
  79. 79.
    Himwich, H.E.: Indolamines and the Schizophrenias. In: Biochemistry, Schizophrenias and Effective Illnesses (Ed. by Harold E. Himwich ), S. 79. Baltimore: Williams and Wilkins 1970Google Scholar
  80. 80.
    Himwich, H.E.: Indolamines and the Depression. In: Biochemistry, Schizophrenias, and Affective Illnesses (Ed. by Harold E. Himwich), S. 230. Baltimore: Williams and Wilkins 1970Google Scholar
  81. 81.
    Holzbauer, M., Vogt, M.: Depression by reserpine of the noradrenaline concentration in the hypothalamus of the cat. J.Neurochem. 1, 8 (1956)PubMedCrossRefGoogle Scholar
  82. 82.
    Jolly, F.: Über Myasthenia gravis pseudoparalytica. Berl.klin.Wschr. 32, 1 (1895)Google Scholar
  83. 83.
    Katz, B., Miledi, R.: The characteristics of „end-plate noise“ produced by different depolarizing drugs. J.Physiol. (Lond.) 230, 707 (1973)Google Scholar
  84. 84.
    Katz, B., Miledi, R.: The bindings of acetylcholine to receptors and its removal from the synaptic cleft. J.Physiol. (Lond.) 231, 549 (1973)Google Scholar
  85. 85.
    Klaue, R.: Parkinsonsche Krankheit (Paralysis agitans) and postencephalitischer Parkinsonismus. Arch.Psychiat. 111, 251 (1940)CrossRefGoogle Scholar
  86. 86.
    Kline, N.S.: Use of reserpine, the newer phenothiazines and iproniazid. Res.Publ.Ass.nerv. ment.Dis. 37, 218 (1959)Google Scholar
  87. 87.
    Kline, N.S., Sacks, W., Simpson, G.M.: Further studies on one day treatment of depression with 5-HTP. Amer J.Psychiat. 121, 379 (1964)PubMedGoogle Scholar
  88. 88.
    Kline, N.S., Stanley, A.M.: Use of reserpine in neuropsychiatric hospital. Ann.N.Y.Acad.Sci. 61, 85 (1955)PubMedCrossRefGoogle Scholar
  89. 89.
    Kuhn, R.: The treatment of depressive states with G22355 (imipramine hydrochloride). AmerJ.Psychiat. 115, 459 (1958)Google Scholar
  90. 90.
    Lambert, E.H.: Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann.N:Y.Acad.Sci. 135, 367 (1966)PubMedCrossRefGoogle Scholar
  91. 91.
    Lambert, E.H., Eaton, L.M., Rooke, E.D.: Defect of neuromuscular conduction associated with malignant neoplasms. AmerJ.Physiol. 187, 612 (1956)Google Scholar
  92. 92.
    Lambert, E.H., Elmqvist, D.: Quantal components of endplate potentials in the myasthenic syndrome. Ann.N.Y.Acad.Sci. 183, 183 (1971)PubMedCrossRefGoogle Scholar
  93. 93.
    Lambert, E.H., Rooke, E.D., Eaton, L.M., Hodgeson, C.H.: Myasthenic Syndrome Occasionally Associated With Bronchial Neoplasm: Neurophysiologic Studies. In: Myasthenia gravis (ed. by H.R. Viets ), S. 362. Springfield/Ill.: C.C. Thomas 1961Google Scholar
  94. 94.
    Lauer, J.W., Inskip, W.M., Bernsohn, J., Zeller, E.A.: Observation on schizophrenic patients after iproniazid and tryptophan. Arch.Neurol.Psychiat. (Chic.) 80, 122 (1958)Google Scholar
  95. 95.
    Lennon, V.A., Lindström, J.M., Seybold, M.E.: Experimental autoimmune myasthenia: A model for myasthenia gravis in rats and guinea pigs. J.exp.Med. 141, 1365 (1975)PubMedCrossRefGoogle Scholar
  96. 96.
    Lindstrom, J.: The cause of myasthenia gravis. New Scientist 1, 228 (1976)Google Scholar
  97. 97.
    Maas, J.W., Fawcett, J.A., Dekirmenjian, H.: 3-Methoxy-4-hydroxyphenylglycol (MHPG) excretion in depressive states. Arch. gen. Psychiat. 19, 129 (1968)PubMedCrossRefGoogle Scholar
  98. 98.
    Maas, J.W., Fawcett, J.A., Dekirmenjian, H.: Catecholamine metabolism in depressive illness with particular reference to response to treatment. Presented at the annual meeting. Amer. Psychiat. Ass., Washington, D.C., May 1–5, 1971Google Scholar
  99. 99.
    Maas, J.W., Landis, D.H.: In vivo studies of the rates of appearance in urine of metabolites of brain norepinephrine. Fed. Proc. 26, 463 (1967)Google Scholar
  100. 100.
    Margolies, C.H.: Pharmacotherapy in psychiatry: a review. Ann.N.Y.Acad.Sci. 66, 698 (1957)CrossRefGoogle Scholar
  101. 101.
    Matz, D.R., Rolf, L.H., Brune, G.G.: Serotoninstoffwechsel bei idiopathischen Grand mal Anfällen. (Eingereicht zur Publikation)Google Scholar
  102. 102.
    McGeer, P.L., Boulding, J.E., Gibson, W.C. et al.: Druginduced extrapyramidal reactions: Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. J.Amer.med. Ass. 177, 665 (1961)Google Scholar
  103. 103.
    McGeer, P.L., McGeer, E.G., Wada, J.A.: A central aromatic amine levels and behavior. II. Serotonin and catecholamine levels in various cat brain areas following administration of psychoactive drugs or amine precursors. Arch. Neurol. (Chic.) 9, 81 (1963)CrossRefGoogle Scholar
  104. 104.
    Mendels, J., Frazer, A., Fitzgerald, R.G., Ramsey, T.A., Sokes, J.W.: Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science 175, 1380 (1972)PubMedCrossRefGoogle Scholar
  105. 105.
    Mendels, J., Secunda, S.K., Dyson, W.L.: A controlled study of the antidepressant effects of lithium. Arch.gen.Psychiat. 26, 154 (1972)PubMedCrossRefGoogle Scholar
  106. 106.
    Mertens, H.G., Hertel, G.: Immundepressive Behandlung von Myasthenie and Polymyositis. Med.Welt 24, 955 (1973)PubMedGoogle Scholar
  107. 107.
    Muller, J.C., Pryor, W.W., Gibbons, J.E., Orgain, E.S.: Depression and anxiety occuring during Rauwolfia therapy. J.Amer.med.Ass. 159, 836 (1955)CrossRefGoogle Scholar
  108. 108.
    Nastuk, W.L., Plescia, OJ., Osserman, K.E.: Changes in serum complement activity in patients with myasthenia gravis. Proc.Soc.exp.Biol. (N.Y.) 105, 177 (1960)Google Scholar
  109. 109.
    Ng, K.Y., Chase, T.N., Colburn, T.W., Kopin, I.J.: L-DOPA induced release of cerebral monoamines. Science 170, 76 (1970)PubMedCrossRefGoogle Scholar
  110. 110.
    Nybäck, H., Sedvall, G., Kopin, I.J.: Accelerated synthesis of dopamine-14C from tyrosine-14C in rat brain after chlorpromazine. Life Sci. 6, 2307 (1967)PubMedCrossRefGoogle Scholar
  111. 111.
    Osborne, R.H., Bradford, H.F., Jones, D.G.: Patterns of amino acid release from nerve endings isolated from spinal cord and medulla. J.Neurochem. 21, 407 (1973)PubMedCrossRefGoogle Scholar
  112. 112.
    Otsuka, M., Endo, M.: The effect of guanidine on neuromuscular transmission. J.Pharmacol. exp.Ther. 128, 273 (1960)PubMedGoogle Scholar
  113. 113.
    Paasonen, M.K., Vogt, M.: The effect of drugs on the amounts of substance P and 5-hydroxytryptamine in mammalian brain. J.Physiol. (Lond.) 131, 617 (1956)Google Scholar
  114. 114.
    Papesche, R., McClure, D.J.: Homovanillic and 5-hydroxyindolacetic acid in cerebrospinal fluid of depressed patients. Arch.gen.Psychiat. 25, 354 (1971)CrossRefGoogle Scholar
  115. 115.
    Parkinson, J.: An essay on the shaking palsy. Reprinted in Medical Classics, Vol. 2. Baltimore: Williams and Wilkins 1938Google Scholar
  116. 116.
    Pletscher, A., Bartholini, G., Gey, K.F., Jenni, A.: Die biochemischen Grundlagen für die Behandlung des Parkinson-Syndroms mit L-Dopa. Schweiz.med.Wschr. 100, 797 (1970)PubMedGoogle Scholar
  117. 117.
    Pletscher, A., Gey, K.F.: Topographical differences in the cerebral metabolism of DL-2–14C3,4dihydroxyphenylalanine. Experientia (Basel) 18, 512 (1962)CrossRefGoogle Scholar
  118. 118.
    Pletscher, A., Shore, P.A., Brodie, B.B.: Serotonin release as a possible mechanism of reserpine action. Science 122, 374 (1955)PubMedCrossRefGoogle Scholar
  119. 119.
    Post, R.M., Kotin, J., Goodwin, F.K., Gordon, E.K.: Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Amer.J.Psychiat. 130, 67 (1973)PubMedGoogle Scholar
  120. 120.
    van Praag, H.M., Kord, J.: Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: a biochemical classification. Psychopharmacologia (Berl.) 19, 148 (1971)CrossRefGoogle Scholar
  121. 121.
    Prange, A., Wilson, O., Lynn, C.W. et al.: L-Tryptophan in mania: Contribution to a permissive hypothesis of affective disorders. Arch.gen.Psychiat. 30, 56 (1974)PubMedCrossRefGoogle Scholar
  122. 122.
    Przuntek, D.: Zur Therapie des Parkinson-Syndroms. Wirkung and Nebenwirkungen der Behandlung mit L-Dopa and einem Dekarboxylasehemmer. Fortschr.Med. 91, 399 (1973)Google Scholar
  123. 123.
    Ricker, R., Doll, W.: Guanidinbehandlung des Botulismus. Z.Neurol. 341, 198 (1970)Google Scholar
  124. 124.
    Rinne, U.K., Birket-Smith, E., Dupont, E., Hansen, E., Hyppä, Marttila, R., Mikkelsen, B., Pakkenberg, H., Presthus, J.: Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (MadoparR) in the treatment of Parkinson’s disease. J.Neurol. 211, 1 (1975)Google Scholar
  125. 125.
    Russell, D.S.: Histological changes in the striped muscles in myasthenia gravis. J.Path.Bact. 65, 279 (1953)PubMedCrossRefGoogle Scholar
  126. 126.
    Sacks, O.W., Marjorie, B.Ch., Kohl, S., Messeloff, Ch.R., Schwartz, W.F.: Effects of levodopa in parkinsonian patients with dementia. Neurology (Minneap.) 22, 516, (1972)CrossRefGoogle Scholar
  127. 127.
    Sano, I., Gamo, T., Kakimoto, Y., Taniguchi, K., Takesada, M., Nishinuma, K.: Distribution of catechol compounds in human brain. Biochim.biophys.Acta (Amst.) 32, 586 (1959)CrossRefGoogle Scholar
  128. 128.
    Santa, T., Engel, A.G., Lambert, E.H.: Histometric study of neuromuscular junction ultra-structure. I. Myasthenia gravis. Neurology (Minneap.) 22, 71 (1972)CrossRefGoogle Scholar
  129. 129.
    Satyamurti, S., Drachman, D.B., Slone, F.: Blockade of acetylcholine receptors: a model of myasthenia gravis. Science 187, 955 (1975)PubMedCrossRefGoogle Scholar
  130. 130.
    Schanberg, S.M., Schildkraut, J.J., Breese, G.R., Kopin, I.J.: Metabolism of normetanephrineH3 in rat brainidentification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem.Pharmacol. 17, 247 (1968)PubMedCrossRefGoogle Scholar
  131. 131.
    Schildkraut, J.J.: The catecholamine hypothesis of affective disorders: A review of supporting evidence. Amer.J.Psychiat. 122, 509 (1965)PubMedGoogle Scholar
  132. 132.
    Schildkraut, J.J., Schanberg, S.M., Kopin, I.J.: Effects of lithium in an H3-norepinephrine metabolism in brain. Life Sci. 5, 1479 (1966)PubMedCrossRefGoogle Scholar
  133. 133.
    Schwartz, M.S., Sargeant, M.K., Swash, M.: Neostigmineinduced end-plate proliferation in the rat. Neurology (Minneap.) 27, 289 (1977)CrossRefGoogle Scholar
  134. 134.
    Seeman, P., Lee, T.: Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217 (1975)PubMedCrossRefGoogle Scholar
  135. 135.
    Shaw, D.M., Camps, F.E., Eccleston, E.: 5-hydroxytryptamine in the hind-brain of depressive suicide. Brit.J.Psychiat. 113, 1407 (1967)PubMedCrossRefGoogle Scholar
  136. 136.
    Shaywitz, B.A., Cohen, D.J., Bowers, M.B. jr.: Reduced cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid in children with epilepsy. Neurology (Minneap.) 25, 72 (1975)CrossRefGoogle Scholar
  137. 137.
    Sheard, M.H., Aghajanian, G.K.: Neuronally activated metabolism of brain serotonin: Effect of lithium. Life Sci. 9, 285 (1970)PubMedCrossRefGoogle Scholar
  138. 138.
    Shopsin, B., Wilk, S., Gershon, S., Davis, K., Suhl, M.: Cerebrospinal fluid MHPG: An assessment of norepinephrine metabolism in affective disorders. Arch.gen.Psychiat. 28, 230 (1973)PubMedCrossRefGoogle Scholar
  139. 139.
    Simpson, J.A.: Myasthenia gravis as an autoimmune disease; clinical aspects. Ann.N.Y.Acad. Sci. 135, 506 (1966)PubMedCrossRefGoogle Scholar
  140. 140.
    Sloan, H.E. jr.: Thymus in myasthenia gravis with observations on the normal anatomy and histology of the thymus. Surgery 13, 154 (1943)Google Scholar
  141. 141.
    Sloane, R.B., Hughes, W., Haust, H.L.: Catecholamine excretion in manic-depressive and schizophrenic psychosis and its relationship to symptomatology. Canad. psychiat. Ass. J. 11, 6 (1966)Google Scholar
  142. 142.
    Snyder, S.H., Shailesh, P.B., Yamamura, H.I., Greenberg, D.: Drugs, Neurotransmitters, and Schizophrenia. Science 184, 1243 (1974)PubMedCrossRefGoogle Scholar
  143. 143.
    Spector, S., Hirsch, C.W., Brodie, B.B.: Association of behavioral effects of pargyline, a nonhydrazide MAO inhibitor with increase in brain norepinephrine. Int.J.Neuropharmacol. 2, 81 (1963)CrossRefGoogle Scholar
  144. 144.
    Spector, S., Shore, P.A., Brodie, B.B.: Biochemical and pharmacological effects of the monoamine oxydase inhibitors, iproniazid, 1-phenyl-2-hydrazinobutane (JB 516) and 1-phenyl3-hydrazinobutane (JB835). J.Pharmacol. exp. Ther. 128, 15 (1960)Google Scholar
  145. 145.
    Sternbach, R.A., Janowsky, D.S., Huey, L.Y., Segal, D.S.: Effects of Altering Brain Serotonin Activity on Human Chronic Pain. In: Advances in Pain Research and Therapy, Vol. 1 (Ed. by J.J. Bonica and D.G. Albe-Fessard ), S. 601. New York: Raven 1976Google Scholar
  146. 146.
    Straus, A.J., Seegal, L., Hsu, B.C., Burkholder, K.C., Nastuk, P.M., Osserman, K.E.: Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc.Soc.exp.Biol. (N.Y.) 105, 177 (1960)Google Scholar
  147. 147.
    Ström-Olsen, R., Weil-Marherbe, H.: Humoral changes in manic-depressive psychosis with particular reference to the excretion of catecholamines in urine. J.ment.Sci. 104, 696 (1938)Google Scholar
  148. 148.
    Sweet, R.D., Fletcher, H., McDowell, Joel, S. et al.: Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology (Minneap.) 26, 305 (1976)CrossRefGoogle Scholar
  149. 149.
    Takahashi, S., Kondo, H., Nobukatsu, K.: Effect of L-5-hydroxytryptophan on brain monoamine metabolism and evalution of its clinical effect in depressed patients. J.psychiat.Res. 12, 177 (1975)PubMedCrossRefGoogle Scholar
  150. 150.
    Torda, C., Wolff, H.G.: Effect of pituitary hormones, cortisone and adrenalectomy on some aspects of neuromuscular function and acetylcholine synthesis. Amer.J.Physiol. 16, 534 (1950)Google Scholar
  151. 151.
    Toyka, K.V., Drachman, D.B., Griffin, D.E. et al.: Myasthenia gravis. Study of humoral immune mechanism by passive transfer to mice. New Engl. J. Med. 296, 125 (1977)Google Scholar
  152. 152.
    Tretiakoff, C.: Contribution à l’étude de l’anatomie pathologique de locus niger de Sommering avec quelques réductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Th2se méd, Paris No. 293, 1919Google Scholar
  153. 153.
    Udenfriend, S., Weissbach, H., Bogdansky, D.F.: Biochemical Studies on Serotonin and Their Physiological Implications. In: Hormones, Brain, Functions, and Behavior (H. Hoagland, ed.), S. 147. New York: Academic Press 1957Google Scholar
  154. 154.
    Vogt, M.: The concentration of sympathin in different parts of the central nervous system under normal conditions and after administration of drugs. J.Physiol. 123, 451 (1954)PubMedGoogle Scholar
  155. 155.
    Werman, R., Davidoff, R.A., Aprison, M.H.: Inhibitory action of glycine on spinal neurons in the cat. J.Neurophysiol. 31, 81 (1968)PubMedGoogle Scholar
  156. 156.
    Wilk, S., Shopsin, B., Gershon, S., Suhl, M.: Cerebrospinal fluid levels of MHPG in affective disorders. Nature (Lond.) 235, 440 (1972)CrossRefGoogle Scholar
  157. 157.
    Wurtman, R.J., Romero, J.A.: Effects of levodopa on nondopaminergic brain neurons. Neurology (Minneap.) 22, 72 (1972)CrossRefGoogle Scholar
  158. 158.
    Yahr, M.D., Wolf, A., Antunes, J.L., Miyoshi, K., Duffy, Ph.: Autopsy findings in parkinsonism following treatment with levodopa. Neurology (Minneap.) 22, 56 (1972)CrossRefGoogle Scholar
  159. 159.
    Zeller, E.A.: The role of amine oxydase in the destruction of catecholamines. Pharmacol. Rev. 11, 387 (1959)PubMedGoogle Scholar
  160. 160.
    Zumstein, H., Siegfried, J.: Mortality among parkinson patients treated with L-Dopa combined with a decarboxylase inhibitor. Europ. Neurol. 14, 321 (1976)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • G. Brune
  • H.-W. Richter

There are no affiliations available

Personalised recommendations